Skip to main content
. 2019 Mar 21;5(6):833–840. doi: 10.1001/jamaoncol.2019.0001

Figure 3. Subgroup Analyses of Progression-Free Survival.

Figure 3.

A, Horizontal lines represent the hazard ratio (HR) for patients assigned to docetaxel plus cisplatin (DP) treatment compared with those assigned to doxorubicin plus cisplatin (AP) treatment. B, Horizontal lines represent the HR for patients assigned to paclitaxel plus carboplatin (TC) treatment compared with those assigned to AP. FIGO 1988 indicates the International Federation of Gynecology and Obstetrics surgical staging system developed in 1988.